VJHemOnc Podcast

iwNHL Session IV: T-cell therapies for NHL: CAR-T therapies & third-party EBV T-cells

The 19th International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2022 took place in Barcelona, Spain, and brought together leading experts in the field as they discussed several topics. In this podcast series, you will hear the latest updates in NHL and gain an insight into the sessions that took place at this year’s meeting.

In this podcast, Catherine Bollard, MBChB, MD, FRACP, FRCPA, Children's National Health System, Washington, DC, Jeremy Abramson, MD, Massachusetts General Hospital Cancer Center, Boston, MA, Barbara Savoldo, MD, PhD, UNC School of Medicine, Chapel Hill, NC, and Maksim Mamonkin, PhD, Baylor College of Medicine, Houston, TX, discuss the latest updates in T-cell therapies for the treatment of NHL, commenting on real-world data on CD19-directed CAR-Ts, and exploring the potential of other T-cell therapies including CD30, CD20, and CD5-directed CAR-Ts in T-cell lymphomas. 

Key updates in CLL: novel treatment strategies, the changing role of chemotherapy, and more

The treatment landscape of chronic lymphocytic leukemia (CLL) has transformed over the years with the increased use of Bruton's tyrosine kinase (BTK) inhibitors, which have demonstrated promising results in several clinical trials. 

In this podcast, leading experts Nitin Jain, MD, University of Texas MD Anderson Cancer Center, Houston, TX, and Catherine Coombs, MD, UC Irvine Health, Orange, CA, discuss key updates in CLL, including the changing role of chemotherapy in the era of novel agents, the promise of next-generation BTK inhibitors, and more. This discussion took place at the 10th Annual Meeting of the Society of Hematologic Oncology (SOHO), which was held in Houston, TX, from September 28-October 1.

iwAL 2022 Session IV: The evolving treatment landscape in ALL and the growing role of immunotherapies

The 4th International Workshop on Acute Leukemias (iwAL) 2022 took place in Nice, France, and brought together leading experts in the field as they discussed several topics. In this podcast series, you will hear the latest updates in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and gain an insight into the sessions that took place at this year’s meeting.

In this podcast, you will hear from Bijal Shah, MD, H. Lee Moffitt Cancer Center, Tampa, FL, Sabina Chiaretti, MD, PhD, Sapienza University of Rome, Rome, Italy, Elias Jabbour, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, and Nicolas Boissel, MD, PhD, Saint-Louis Hospital, Paris, France, who discuss the evolving treatment landscape in ALL, debating the role of immunotherapies, including antibody-drug conjugates (ADCs) and CAR-T cells.

iwNHL Session III: Exploring the optimal management of R/R follicular lymphoma in an expanding treatment landscape

The 19th International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2022 took place in Barcelona, Spain, and brought together leading experts in the field as they discussed several topics. In this podcast series, you will hear the latest updates in NHL and gain an insight into the sessions that took place at this year’s meeting.

This podcast episode focuses on the optimal management of relapsed/refractory (R/R) follicular lymphoma (FL), where you will hear from Laura Pasqualucci, MD, Columbia University Irving Medical Center, New York, NY, Jessica Okosun, MA, MB BChir, MRCP, FRCPath, PhD, Barts Cancer Institute, Queen Mary University of London, London, UK, and David Qualls, MD, Memorial Sloan Kettering Cancer Center, New York, NY. The experts debate on how to best treat, combine, and sequence therapies in R/R FL, and further comment on the role of epigenetic alterations in this disease. 

iwAL 2022 Session III: Novel targets, combinations and treatment strategies in AML

The 4th International Workshop on Acute Leukemias (iwAL) 2022 took place in Nice, France, and brought together leading experts in the field as they discussed several topics. In this podcast series, you will hear the latest updates in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and gain an insight into the sessions that took place at this year’s meeting.

In this podcast, Richard Stone, MD, Dana-Farber Cancer Institute, Boston, MA, David Sallman, MD, H. Lee Moffitt Cancer Center, Tampa, FL, and Thomas Cluzeau, MD, PhD, Central University Hospital of Nice, Nice, France, discuss novel targets and combinations in AML, treatment approaches for patients with TP53-mutated disease, and more. 

Recent updates in CML: treatment strategies, clinical trials, and novel agents

The 10th Annual Meeting of the Society of Hematologic Oncology (SOHO) was held in Houston, TX, from September 28-October 1, and brought together leading experts to discuss recent advances in hematological malignancies.

In this podcast, you will hear from experts Jorge Cortes, MD, Augusta University, Augusta, GA, and Mhairi Copland, MB ChB, PhD, University of Glasgow, Glasgow, UK, who discuss the latest in chronic myeloid leukemia (CML), including treatment strategies for patients with multiple refractory disease, and novel agents in the field. The experts also comment on clinical trial updates, including data from the OPTIC trial (NCT02467270) and the ASCEMBL trial (NCT03106779).

iwNHL Session II: Understanding and harnessing the immune microenvironment against lymphoma

The 19th International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2022 took place in Barcelona, Spain, and brought together leading experts in the field as they discussed several topics. In this podcast series, you will hear the latest updates in NHL and gain an insight into the sessions that took place at this year’s meeting.

The second session from iwNHL focused on the role of the tumor immune microenvironment in lymphoma. In this podcast, John Gribben, MD, DSc, FRCP, FRCPath, FMed Sci, Barts Cancer Institute, London, UK, Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN, John Kuruvilla, MD, FRCPC, Princess Margaret Cancer Center, Toronto, Canada, and Gaël Roué, PhD, Josep Carreras Leukemia Research Institute, Barcelona, Spain, discuss the importance of understanding the tumor immune microenvironment in NHL. The experts outline strategies to engage the innate and adaptive anti-tumor immune response, and explain how this can be used to enhance the efficacy of immune therapies. 

iwAL 2022 Session II: Novel treatment strategies in ALL

The 4th International Workshop on Acute Leukemias (iwAL) 2022 took place in Nice, France, and brought together leading experts in the field as they discussed several topics. In this podcast series, you will hear the latest updates in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and gain an insight into the sessions that took place at this year’s meeting.

In this podcast, Robin Foà, MD, Sapienza University of Rome, Rome, Italy, Rob Pieters, MD, PhD, Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands, Nicholas Short, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, and Nicolas Boissel, MD, PhD, Saint-Louis Hospital, Paris, France, discuss novel treatment strategies in ALL, including the role of combination approaches and antibody drug conjugates, and more.

The role of the innate immune system in MDS

Myelodysplastic syndromes (MDS) represent a heterogeneous group of diseases which remain a challenge to treat, and immune dysregulation has been found to play a key role in the pathogenesis of MDS. There is a growing interest, by researchers, as well as clinicians, to better understand the role of the innate immune system in this disease, and further investigate novel agents and strategies to treat patients at an earlier stage. 

In this podcast, you will hear from leading experts Rafael Bejar, MD, PhD, University of California San Diego, San Diego, CA, Rashmi Kanagal-Shamanna, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, and David Sallman, MD, Moffitt Cancer Center, Tampa, FL, who discuss the role of the innate immune system in MDS, and further highlight the role of chronic inflammation in this disease, as well as future therapeutic strategies. 

iwAL 2022 Session I: The standard of care in AML in 2022

The 4th International Workshop on Acute Leukemias (iwAL) 2022 took
place in Nice, France, and brought together leading experts in the field as
they discussed several topics. In this podcast series, you will hear the
latest updates in acute myeloid leukemia (AML) and acute lymphoblastic
leukemia (ALL) and gain an insight into the sessions that took place at this
year’s meeting.

The first session from iwAL focused on the standard of care in AML in
2022. In this podcast, Mark Levis, MD, PhD, Johns Hopkins Sidney Kimmel
Comprehensive Cancer Center, Baltimore, MD, Eunice Wang, MD, Roswell
Park Comprehensive Cancer Center, Buffalo, NY, Jessica Altman, MD,
Robert H. Lurie Comprehensive Cancer Center, Northwestern University,
Chicago, IL, and Charles Craddock, CBE, FRCP, FRCPath, DPhil, University
of Birmingham, Birmingham, UK, discuss and debate the current standard
of care in AML in 2022, commenting on the role of transplantation and
novel agents, as well as treatment approaches for relapsed FLT3-mutated
disease.